Display options
Cite
Nassar AH, Abdul-Jawad BM, Barnes DS. Hepatic Failure Due to Cholestatic Hepatitis C in an Immunosuppressed Patient Treated With Elbasvir and Grazeprevir. ACG Case Rep J. 2018;5:e6doi: 10.14309/crj.2018.6.
Nassar, A. H., Abdul-Jawad, B. M., & Barnes, D. S. (2018). Hepatic Failure Due to Cholestatic Hepatitis C in an Immunosuppressed Patient Treated With Elbasvir and Grazeprevir. ACG case reports journal, 5e6. https://doi.org/10.14309/crj.2018.6
Nassar, Amin H, et al. "Hepatic Failure Due to Cholestatic Hepatitis C in an Immunosuppressed Patient Treated With Elbasvir and Grazeprevir." ACG case reports journal vol. 5 (2018): e6. doi: https://doi.org/10.14309/crj.2018.6
Nassar AH, Abdul-Jawad BM, Barnes DS. Hepatic Failure Due to Cholestatic Hepatitis C in an Immunosuppressed Patient Treated With Elbasvir and Grazeprevir. ACG Case Rep J. 2018 Jan 17;5:e6. doi: 10.14309/crj.2018.6. eCollection 2018. PMID: 29392153; PMCID: PMC5772065.
Copy Download .nbib Format: NLM
Share it on

ACG Case Rep J. 2018 Jan 17;5:e6. doi: 10.14309/crj.2018.6. eCollection 2018.

Hepatic Failure Due to Cholestatic Hepatitis C in an Immunosuppressed Patient Treated With Elbasvir and Grazeprevir.

ACG case reports journal

Amin H Nassar, Baraa M Abdul-Jawad, David S Barnes

Affiliations

  1. Department of Pulmonary Medicine and Critical Care, Brigham and Women's Hospital, Boston, MA.
  2. Department of Gastroenterology and Hepatology, Cleveland Clinic, Cleveland, OH.

PMID: 29392153 PMCID: PMC5772065 DOI: 10.14309/crj.2018.6

Abstract

Hepatitis C-induced cholestatic hepatitis is a well-known fatal complication of postorthotropic liver transplantation and prolonged immunosuppression. Recent studies on direct-acting antiviral agents have shown promising results in terms of morbidity and mortality of this condition in postorthotropic liver, heart, and renal transplant patients. However, hepatitis C-induced cholestatic hepatitis remains a highly fatal condition in non-transplant patients. We report the first-ever use of the oral direct-acting antiviral combination, elbasvir and grazeprevir, in the treatment of a non-liver transplant patient with cholestatic hepatitis.

References

  1. Liver Transpl. 2010 Nov;16(11):1228-35 - PubMed
  2. Ann Hepatol. 2007 Jul-Sep;6(3):186-9 - PubMed
  3. Hepatology. 1999 Nov;30(5):1293-8 - PubMed
  4. Am J Gastroenterol. 2002 Feb;97(2):478-83 - PubMed
  5. Hepatology. 1991 Jan;13(1):150-7 - PubMed
  6. J Hepatol. 2015 Jan;62(1):234-7 - PubMed
  7. Transplant Proc. 2011 Jan-Feb;43(1):259-62 - PubMed
  8. Liver Transpl Surg. 1999 Jul;5(4):294-300 - PubMed
  9. J Formos Med Assoc. 2017 May;116(5):407-409 - PubMed
  10. Rom J Morphol Embryol. 2007;48(1):51-4 - PubMed
  11. Ann Hepatol. 2015 Sep-Oct;14(5):756-61 - PubMed
  12. Am J Transplant. 2006 Dec;6(12):2983-93 - PubMed
  13. Gastroenterology. 1992 Mar;102(3):956-62 - PubMed
  14. Am J Pathol. 1990 Sep;137(3):667-76 - PubMed
  15. Gastroenterology. 2015 Sep;149(3):649-59 - PubMed

Publication Types